date:Sep 06, 2013
such as Blackstone (BX.N), Lion Capital, Cinven CINV.UL, CVC Capital Partners CVC.UL and KKR (KKR.N). All have declined to comment.
Lucozade and Ribena no longer fit well in GSK's portfolio, since the company is focusing its consumer health operations increasingly on emerging markets, where both brands are relatively weak.
Both are veteran products - Lucozade was launched in 1927 and Ribena introduced 10 years later - yet they remain popular in Britain where they command a prominent position